September 26, 2017

Veru Inc. Announces Initiation of Telemedicine Capability to Expand Access to Prescriptions for FC2 Female Condom

MIAMI, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU), (formerly, Nasdaq:FHCO) (”Veru” or the “company”), a biopharmaceutical company focused on urology and oncology, today announced the launch of its telemedicine capability to allow women and men better access to FC2 by being able to obtain a prescription online for the FC2 female condom.

Interested parties will be able to download an application to their smartphone called “Hey Doctor,” which will connect them to a page to request a prescription online. This prescription will be automatically sent to any participating pharmacy, where they can obtain the product. The prescription will be eligible for up to three month’s supply of FC2. Currently the service is available in Arizona, California, Connecticut, Florida, Georgia, Illinois, Montana, New York, Ohio, Pennsylvania, Rhode Island, Virginia and Washington. The company is working to bring the service nationwide. The “Hey Doctor” application is currently available for the Apple operating system, with Android format capability expected soon. More information on “Hey Doctor” and FC2 can be found at www.fc2.com.

“Telemedicine provides an important alternative to visiting a doctor for a prescription for FC2. First, it allows women and men who may not have readily available access to a primary care physician, whether because of geographic or insurance reasons, to still get the FC2 product. More importantly, it ensures that anyone who wants to obtain a prescription can do so in a safe, confidential and convenient manner. Our goal is to provide people who need or desire FC2 with unfettered access,” said Mitchell Steiner, MD, president and CEO of Veru. “While the company’s focus remains on the development and commercialization of multiple urology and oncology products primarily via the 505(b)(2) development pathway, we are proud to be able to help safeguard the population’s health by facilitating secure and convenient access to FC2. Furthermore, the FC2 prescription program has become a new and growing revenue source for Veru. Telemedicine added to our sales force will help to further accelerate US growth of FC2 product sales.”

About Veru Inc.
Veru Inc. (Veru) is a biopharmaceutical company focused on urology and oncology. Veru utilizes FDA's 505(b)(2) regulatory approval pathway to develop and commercialize drug candidates. FDA's 505(b)(2) regulatory approval pathway is designed to allow for potentially expedited regulatory approval based on a previously established safety and efficacy profile of the product. Veru is developing products under the 505(b)(1) pathway as well, which is the

traditional new drug application (NDA) pathway. The company is currently developing drug product candidates for benign prostatic hyperplasia (BPH or enlarged prostate), hot flashes associated with prostate cancer hormone treatment, male infertility and novel oral chemotherapy (alpha & beta tubulin inhibitor) for a variety of malignancies, including metastatic prostate, breast and ovarian cancers. In addition, the company markets and sells the FC2 Female Condom® (now available by prescription in the US) and PREBOOST® medicated individual wipe, which is a male genital desensitizing drug product for the prevention of premature ejaculation.

The company's division, The Female Health Company, is focused on the global public health sector FC2 business. This division markets the company's Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.

More information about Veru and its products can be found atwww.veruhealthcare.com, www.PREBOOST.com and www.fc2femalecondom.com. For corporate and investor-related information about the Company, please visit https://veruhealthcare.com/investors.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: *The statements in this release that are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements in this release are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations; risks related to the development of the Company's product portfolio, including clinical trials, regulatory approvals and time and cost to bring to market; many of the Company's products are at an early stage of development and the Company may fail to successfully commercialize such products; risks related to intellectual property, including licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay or restructuring; a governmental tender award indicates acceptance of the bidder's price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government*

pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; risks related to the costs and other effects of litigation; the Company's ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company's ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2016. These documents are available on the "SEC Filings" section of our website at www.veruhealthcare.com/investors.

Contact:
Kevin Gilbert
Veru Inc.
786-322-2213
KGilbert@veruhealthcare.com

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

Source: Veru Inc.